argenx SE (NASDAQ:ARGX) Receives $630.42 Consensus Target Price from Analysts

argenx SE (NASDAQ:ARGX - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-three ratings firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, nineteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $630.42.

A number of equities analysts have recently issued reports on ARGX shares. Wolfe Research raised argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price target on the stock in a research report on Tuesday, November 12th. Evercore ISI boosted their price objective on shares of argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. William Blair raised shares of argenx from a "market perform" rating to an "outperform" rating in a report on Friday, November 1st. Truist Financial upped their price target on shares of argenx from $540.00 to $660.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Finally, Oppenheimer reissued an "outperform" rating and set a $675.00 target price (up from $646.00) on shares of argenx in a research note on Thursday, November 21st.

Institutional Trading of argenx

A number of hedge funds have recently bought and sold shares of the business. Profund Advisors LLC grew its stake in shares of argenx by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company's stock valued at $418,000 after buying an additional 28 shares during the period. Raymond James Trust N.A. boosted its position in argenx by 6.0% in the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company's stock valued at $268,000 after buying an additional 28 shares during the period. Wealth Alliance boosted its position in argenx by 4.8% in the 2nd quarter. Wealth Alliance now owns 628 shares of the company's stock valued at $270,000 after buying an additional 29 shares during the period. GAMMA Investing LLC raised its holdings in shares of argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company's stock valued at $51,000 after purchasing an additional 40 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its holdings in shares of argenx by 8.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company's stock valued at $286,000 after purchasing an additional 43 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Trading Up 1.2 %

Shares of argenx stock traded up $7.43 on Thursday, hitting $614.59. 405,338 shares of the company traded hands, compared to its average volume of 310,991. The stock's 50 day moving average price is $562.49 and its 200-day moving average price is $493.62. argenx has a 52 week low of $327.73 and a 52 week high of $620.28. The company has a market cap of $37.10 billion, a PE ratio of -698.40 and a beta of 0.61.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter in the previous year, the firm posted ($1.25) earnings per share. As a group, research analysts anticipate that argenx will post 2.2 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.